Ran Nussbaum Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Ran Nussbaum.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Ran Nussbaum. Ran Nussbaum is Director in ARQULE INC ($ARQL) and in Eloxx Pharmaceuticals, Inc. ($ELOX) and Director in Eloxx Pharmaceuticals, Inc. ($ELOX) and Director in Kite Pharma, Inc. ($KITE) and Director in Keros Therapeutics, Inc. ($KROS) and Director in UroGen Pharma Ltd. ($URGN) and Director in Prevail Therapeutics Inc. ($PRVL).
Latest Insider Trading Transactions of Ran Nussbaum
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARQL, ELOX, KROS, KITE, PRVL, URGN
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 17 2021 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 1.35 | 592,592 | 799,999 | 616,592 | 24 K to 616.6 K (+2,469.13 %) |
| May 17 2021 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 1.35 | 1,422,222 | 1,920,000 | 1,989,551 | 567.3 K to 2 M (+250.69 %) |
| May 17 2021 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 1.35 | 2,630,487 | 3,551,157 | 3,679,797 | 1 M to 3.7 M (+250.69 %) |
| May 17 2021 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 1.35 | 1,280,624 | 1,728,842 | 1,791,470 | 510.8 K to 1.8 M (+250.69 %) |
| Apr 22 2021 | URGN | UroGen Pharma Ltd. | Nussbaum Ran | Director | Option Exercise | M | 5.00 | 1,030 | 5,150 | 0 | |
| Apr 22 2021 | URGN | UroGen Pharma Ltd. | Nussbaum Ran | Director | Buy | M | 5.00 | 1,030 | 5,150 | 1,465,199 | 1.5 M to 1.5 M (+0.07 %) |
| Jan 26 2021 | PRVL | Prevail Therapeuti ... | Nussbaum Ran | Director | Option Exercise | D | 16.98 | 17,000 | 288,660 | 0 | |
| Jan 26 2021 | PRVL | Prevail Therapeuti ... | Nussbaum Ran | Director | Sell | U | 0.00 | 1,576,881 | 0 | 0 | 1.6 M to 0 (-100.00 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 6,000 | 300,000 | 155,262 | 149.3 K to 155.3 K (+4.02 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 14,400 | 720,000 | 1,228,326 | 1.2 M to 1.2 M (+1.19 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 12,966 | 648,300 | 1,122,768 | 1.1 M to 1.1 M (+1.17 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 50.00 | 26,634 | 1,331,700 | 2,288,151 | 2.3 M to 2.3 M (+1.18 %) |
| Jun 19 2020 | PRVL | Prevail Therapeuti ... | Nussbaum Ran | Director | Option Exercise | A | 16.98 | 17,000 | 288,660 | 17,000 | |
| Jun 10 2020 | URGN | UroGen Pharma Ltd. | Nussbaum Ran | Director | Option Exercise | A | 28.24 | 10,000 | 282,400 | 10,000 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 36,858 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 79,653 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 88,460 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 163,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 68,654 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 91,538 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 82,425 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 169,307 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 737,226 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 663,825 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 1,363,542 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 43,750 | 700,000 | 149,262 | 105.5 K to 149.3 K (+41.46 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 105,000 | 1,680,000 | 1,213,926 | 1.1 M to 1.2 M (+9.47 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 94,546 | 1,512,736 | 1,109,802 | 1 M to 1.1 M (+9.31 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 194,203 | 3,107,248 | 2,261,517 | 2.1 M to 2.3 M (+9.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 36,858 | 0 | 105,512 | 68.7 K to 105.5 K (+53.69 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 79,653 | 0 | 1,108,926 | 1 M to 1.1 M (+7.74 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 88,460 | 0 | 1,015,256 | 926.8 K to 1 M (+9.54 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 163,612 | 0 | 2,067,314 | 1.9 M to 2.1 M (+8.59 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 68,654 | 0 | 68,654 | 0 to 68.7 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 91,538 | 0 | 1,029,273 | 937.7 K to 1 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 82,425 | 0 | 926,796 | 844.4 K to 926.8 K (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 169,307 | 0 | 1,903,702 | 1.7 M to 1.9 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 737,226 | 0 | 937,735 | 200.5 K to 937.7 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 663,825 | 0 | 844,371 | 180.5 K to 844.4 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 1,363,542 | 0 | 1,734,395 | 370.9 K to 1.7 M (+367.68 %) |
| Jan 16 2020 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | D | 6.21 | 40,000 | 248,400 | 0 | |
| Jan 16 2020 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | D | 2.48 | 20,000 | 49,600 | 0 | |
| Jan 16 2020 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | D | 1.10 | 30,000 | 33,000 | 0 | |
| Jan 16 2020 | ARQL | ARQULE INC | Nussbaum Ran | Director | Sell | U | 20.00 | 8,611 | 172,220 | 0 | 8.6 K to 0 (-100.00 %) |
| Jan 16 2020 | ARQL | ARQULE INC | Nussbaum Ran | Director | Sell | U | 20.00 | 36,923 | 738,460 | 0 | 36.9 K to 0 (-100.00 %) |
| Jan 16 2020 | ARQL | ARQULE INC | Nussbaum Ran | Director | Sell | U | 20.00 | 2,088,816 | 41,776,320 | 0 | 2.1 M to 0 (-100.00 %) |
| Jan 16 2020 | ARQL | ARQULE INC | Nussbaum Ran | Director | Sell | U | 20.00 | 4,290,550 | 85,811,000 | 0 | 4.3 M to 0 (-100.00 %) |
| Jan 16 2020 | ARQL | ARQULE INC | Nussbaum Ran | Director | Sell | U | 20.00 | 2,319,920 | 46,398,400 | 0 | 2.3 M to 0 (-100.00 %) |
| Dec 27 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | M | 1.75 | 400,558 | 700,977 | 0 | |
| Dec 27 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | M | 1.75 | 823,632 | 1,441,356 | 0 | |
| Dec 27 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | M | 1.75 | 445,524 | 779,667 | 0 | |
| Dec 27 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Payment of Exercise | F | 20.11 | 34,857 | 700,974 | 2,088,816 | 2.1 M to 2.1 M (-1.64 %) |
| Dec 27 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | M | 1.75 | 400,558 | 700,977 | 2,123,673 | 1.7 M to 2.1 M (+23.25 %) |
| Dec 27 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Payment of Exercise | F | 20.11 | 71,674 | 1,441,364 | 4,290,550 | 4.4 M to 4.3 M (-1.64 %) |
| Dec 27 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | M | 1.75 | 823,632 | 1,441,356 | 4,362,224 | 3.5 M to 4.4 M (+23.28 %) |
| Dec 27 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Payment of Exercise | F | 20.11 | 38,770 | 779,665 | 2,319,920 | 2.4 M to 2.3 M (-1.64 %) |
| Dec 27 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | M | 1.75 | 445,524 | 779,667 | 2,358,690 | 1.9 M to 2.4 M (+23.29 %) |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | X | 1.75 | 27,442 | 48,024 | 400,558 | |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | X | 1.75 | 56,368 | 98,644 | 823,632 | |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | X | 1.75 | 30,476 | 53,333 | 445,524 | |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | X | 1.75 | 27,442 | 48,024 | 1,723,115 | 1.7 M to 1.7 M (+1.62 %) |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | X | 1.75 | 56,368 | 98,644 | 3,538,592 | 3.5 M to 3.5 M (+1.62 %) |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | X | 1.75 | 30,476 | 53,333 | 1,913,166 | 1.9 M to 1.9 M (+1.62 %) |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | X | 1.75 | 27,442 | 48,024 | 400,558 | |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | X | 1.75 | 56,368 | 98,644 | 823,632 | |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | X | 1.75 | 30,476 | 53,333 | 445,524 | |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | X | 1.75 | 27,442 | 48,024 | 1,723,115 | 1.7 M to 1.7 M (+1.62 %) |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | X | 1.75 | 56,368 | 98,644 | 3,538,592 | 3.5 M to 3.5 M (+1.62 %) |
| Sep 16 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | X | 1.75 | 30,476 | 53,333 | 1,913,166 | 1.9 M to 1.9 M (+1.62 %) |
| Jul 01 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 9.75 | 36,923 | 359,999 | 36,923 | 0 to 36.9 K |
| Jul 01 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 9.75 | 72,205 | 703,999 | 1,882,690 | 1.8 M to 1.9 M (+3.99 %) |
| Jul 01 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 9.75 | 65,016 | 633,906 | 1,695,673 | 1.6 M to 1.7 M (+3.99 %) |
| Jul 01 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 9.75 | 133,548 | 1,302,093 | 3,482,224 | 3.3 M to 3.5 M (+3.99 %) |
| Jul 01 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 9.75 | 36,923 | 359,999 | 36,923 | 0 to 36.9 K |
| Jul 01 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 9.75 | 72,205 | 703,999 | 1,882,690 | 1.8 M to 1.9 M (+3.99 %) |
| Jul 01 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 9.75 | 65,016 | 633,906 | 1,695,673 | 1.6 M to 1.7 M (+3.99 %) |
| Jul 01 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 9.75 | 133,548 | 1,302,093 | 3,482,224 | 3.3 M to 3.5 M (+3.99 %) |
| Jun 26 2019 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 9.00 | 24,000 | 216,000 | 24,000 | 0 to 24 K |
| Jun 26 2019 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 9.00 | 46,933 | 422,397 | 567,329 | 520.4 K to 567.3 K (+9.02 %) |
| Jun 26 2019 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 9.00 | 86,806 | 781,254 | 1,049,310 | 962.5 K to 1 M (+9.02 %) |
| Jun 26 2019 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 9.00 | 42,261 | 380,349 | 510,846 | 468.6 K to 510.8 K (+9.02 %) |
| Jun 05 2019 | URGN | UroGen Pharma Ltd. | Nussbaum Ran | Director | Option Exercise | A | 34.83 | 10,000 | 348,300 | 10,000 | |
| May 29 2019 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Option Exercise | A | 9.02 | 20,000 | 180,400 | 20,000 | ||
| May 15 2019 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | A | 6.21 | 40,000 | 248,400 | 40,000 | |
| Oct 22 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 5.50 | 43,657 | 240,114 | 1,630,657 | 1.6 M to 1.6 M (+2.75 %) |
| Oct 22 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 5.50 | 89,676 | 493,218 | 3,348,676 | 3.3 M to 3.3 M (+2.75 %) |
| Oct 22 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 5.50 | 48,485 | 266,668 | 1,810,485 | 1.8 M to 1.8 M (+2.75 %) |
| Jun 19 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Option Exercise | A | 23.27 | 40,000 | 930,800 | 40,000 | |
| May 25 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | J | 1.75 | 428,000 | 749,000 | 428,000 | |
| May 25 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | J | 1.75 | 880,000 | 1,540,000 | 880,000 | |
| May 25 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | J | 1.75 | 476,000 | 833,000 | 476,000 | |
| May 25 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | J | 0.00 | 1,587,000 | 0 | 1,587,000 | 0 to 1.6 M |
| May 25 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | J | 0.00 | 3,259,000 | 0 | 3,259,000 | 0 to 3.3 M |
| May 25 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | J | 0.00 | 1,762,000 | 0 | 1,762,000 | 0 to 1.8 M |
| May 18 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Buy | P | 3.29 | 8,611 | 28,330 | 8,611 | 0 to 8.6 K |
| May 10 2018 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | A | 2.48 | 20,000 | 49,600 | 20,000 | |
| May 01 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 9.75 | 93,333 | 909,997 | 520,396 | 427.1 K to 520.4 K (+21.85 %) |
| May 01 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 9.75 | 172,626 | 1,683,104 | 962,504 | 789.9 K to 962.5 K (+21.85 %) |
| May 01 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 9.75 | 84,041 | 819,400 | 468,585 | 384.5 K to 468.6 K (+21.85 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 8.00 | 1,600 | 12,800 | 427,063 | 425.5 K to 427.1 K (+0.38 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 8.00 | 2,959 | 23,672 | 789,878 | 786.9 K to 789.9 K (+0.38 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 8.00 | 1,441 | 11,528 | 384,544 | 383.1 K to 384.5 K (+0.38 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 7.55 | 1,760 | 13,288 | 425,463 | 423.7 K to 425.5 K (+0.42 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 7.55 | 3,255 | 24,575 | 786,919 | 783.7 K to 786.9 K (+0.42 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Nussbaum Ran | Director | Buy | P | 7.55 | 1,585 | 11,967 | 383,103 | 381.5 K to 383.1 K (+0.42 %) |
| Nov 09 2017 | ARQL | ARQULE INC | Nussbaum Ran | Director | Option Exercise | A | 1.10 | 30,000 | 33,000 | 30,000 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | D | 91.21 | 8,810 | 803,560 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | D | 50.87 | 7,000 | 356,090 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | D | 59.23 | 10,000 | 592,300 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | D | 1.35 | 50,000 | 67,500 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 2,632 | 0 | 0 | 2.6 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 1,029 | 0 | 0 | 1 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 2,651 | 0 | 0 | 2.7 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 3,520 | 0 | 0 | 3.5 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | D | 0.00 | 4,360 | 0 | 0 | 4.4 K to 0 (-100.00 %) |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | A | 91.21 | 8,810 | 803,560 | 8,810 | |
| Jun 22 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Grant | A | 0.00 | 2,410 | 0 | 4,360 | 2 K to 4.4 K (+123.59 %) |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 68.94 | 2,632 | 181,450 | 2,632 | 0 to 2.6 K |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 69.17 | 1,029 | 71,176 | 1,029 | 0 to 1 K |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 69.17 | 2,651 | 183,370 | 2,651 | 0 to 2.7 K |
| May 11 2017 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | P | 69.17 | 3,520 | 243,478 | 3,520 | 0 to 3.5 K |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | A | 50.87 | 7,000 | 356,090 | 7,000 | |
| Jun 03 2016 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Grant | A | 0.00 | 1,950 | 0 | 1,950 | 0 to 2 K |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | A | 59.23 | 10,000 | 592,300 | 10,000 | |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 56.08 | 24,070 | 1,349,846 | 0 | 24.1 K to 0 (-100.00 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 55.27 | 200,604 | 11,087,383 | 24,070 | 224.7 K to 24.1 K (-89.29 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 57.38 | 7,800 | 447,564 | 224,674 | 232.5 K to 224.7 K (-3.36 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 56.44 | 3,754 | 211,876 | 232,474 | 236.2 K to 232.5 K (-1.59 %) |
| Jun 03 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 55.05 | 69,206 | 3,809,790 | 236,228 | 305.4 K to 236.2 K (-22.66 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 59.91 | 25,560 | 1,531,404 | 43,604 | 69.2 K to 43.6 K (-36.96 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 59.91 | 23,349 | 1,398,934 | 112,714 | 136.1 K to 112.7 K (-17.16 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 59.91 | 66,948 | 4,011,129 | 149,116 | 216.1 K to 149.1 K (-30.99 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 61.24 | 50,000 | 3,062,050 | 70,000 | 120 K to 70 K (-41.67 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 61.24 | 13,937 | 853,516 | 136,063 | 150 K to 136.1 K (-9.29 %) |
| Mar 31 2015 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Sell | S | 61.24 | 13,936 | 853,455 | 216,064 | 230 K to 216.1 K (-6.06 %) |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 313,531 | 0 | 0 | |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 807,681 | 0 | 0 | |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 1,072,245 | 0 | 0 | |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | C | 0.00 | 314,743 | 0 | 314,743 | 0 to 314.7 K |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | C | 0.00 | 810,803 | 0 | 810,803 | 0 to 810.8 K |
| Jun 27 2014 | KITE | Kite Pharma, Inc. | Nussbaum Ran | Director | Buy | C | 0.00 | 1,076,390 | 0 | 1,076,390 | 0 to 1.1 M |
Page: 1